Panbela Therapeutics, Inc. PBLA
At closeNov 2, 2026, 4:00 PM EST
- YTD
- +5,450.00%
- 1 year
- +5,450.00%
- Market cap
- 53.89K
- EPS (ttm)
- -1,915.86
- Shares out
- 3.48M
- Forward P/E
- -0.02
- YTD return
- +5450.00%
- 1-year return
- +5450.00%
- Volume
- 1.01K
- Avg volume
- 756
- Open
- 0.02
- Previous close
- 0.0111
- Day's range
- 0.02 – 0.02
- 52-week range
- 0.0001 – 2.50
- Beta
- 0.82
- Analysts
- Buy
- Price target
- 410.00 (+3693593.7%)
2Y -0.3589 (-97.00%)
Key statistics
- Enterprise value
- 4.48M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.34M
- Total cash
- 907.00K
- Total debt
- 5.19M
- Return on equity
- 0.00%
- Short % of float
- 3.07%
- 50-day average
- 5.07
- 200-day average
- 30.69
Analyst view
Consensus: buy
- Target (low)
- 320.00
- Target (mean)
- 410.00
- Target (high)
- 500.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -24.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.48 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -2.07 | -1.47 | +0.60 | +28.99% |
| May 15, 2024 | Mar 1, 2024 | -1.23 | -2.28 | -1.05 | -85.37% |
| Mar 26, 2024 | Dec 1, 2023 | -24.34 | -65.90 | -41.56 | -170.75% |
| Nov 9, 2023 | Sep 1, 2023 | -41.20 | -53.80 | -12.60 | -30.58% |
| Aug 10, 2023 | Jun 1, 2023 | -94.20 | -159.00 | -64.80 | -68.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 23, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
- Country
- United States
- Website
- panbela.com
News
Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis 
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript 
Panbela Provides Business Update and Reports Q3 2024 Financial Results 
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript 
Panbela Provides Business Update and Reports Q2 2024 Financial Results 
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024 
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification 
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts 
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript 
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Your note
Sign in to keep a note on PBLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CULLEN MICHAEL T | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 3, 2022 | 0 |
| FRATAMICO ARTHUR R | Director | Stock Award(Grant) | May 24, 2021 | 9,615 |
| GAGNON SUZANNE | Director | Stock Gift | Apr 28, 2021 | 0 |
| GOLDMAN SACHS GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 7, 2023 | 0 |
| HORVATH SUSAN | Chief Financial Officer | Purchase | Jan 29, 2023 | 17,880 |
| JACOB JEFFREY E | Director | Stock Gift | Sep 11, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 7.97% | 235,819 | 542.38K | Jun 29, 2023 |
| Walleye Capital LLC | 3.20% | 94,536 | 217.43K | Jun 29, 2023 |
| Hudson Bay Capital Management Lp | 2.57% | 76,000 | 174.80K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.13% | 3,713 | 8.54K | Jun 29, 2023 |
| UBS Group AG | 0.03% | 823 | 1.89K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.14% | 4,248 | 9.77K | Jun 29, 2023 |